Status:
RECRUITING
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Lead Sponsor:
argenx
Conditions:
Myasthenia Gravis
Eligibility:
All Genders
18+ years
Brief Summary
This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efga...
Eligibility Criteria
Inclusion
- Patients diagnosed with gMG who are expected to start commercial efgartigimod at enrolment or who are within their first cycle of efgartigimod at enrolment or Patients diagnosed with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment
- Have provided appropriate written informed consent
Exclusion
- None
Key Trial Info
Start Date :
November 4 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2034
Estimated Enrollment :
680 Patients enrolled
Trial Details
Trial ID
NCT06298565
Start Date
November 4 2024
End Date
June 1 2034
Last Update
February 17 2026
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center,
San Francisco, California, United States, 94143
2
SFM Clinical Research, LLC
Boca Raton, Florida, United States, 33487
3
University of Florida College of Medicine Jacksonville
Jacksonville Beach, Florida, United States, 32209
4
Medsol Clinical Research Center Inc
Port Charlotte, Florida, United States, 33952